SEARCH

SEARCH BY CITATION

References

  • 1
    Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S4756.
  • 2
    Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 35962.
  • 3
    EASL Clinical Practice Guidelines. management of hepatitis C virus infection. J Hepatol 2011; 55: 24564.
  • 4
    Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 11226.
  • 5
    Maylin S, Martinot M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 8219.
  • 6
    Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32: 88102.
  • 7
    Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 34355.
  • 8
    Yao N, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997; 4: 4637.
  • 9
    Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection : progression of fibrosis and treatment response. J Hepatol 2012; 57: 111025.
  • 10
    Asselah T. Interferon stimulated genes and hepatitis C virus infection. J Interferon Cytokine Res. 2012; 26: 45562.
  • 11
    Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 51624.
  • 12
    Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 1869.
  • 13
    Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Shortterm antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127: 134755.
  • 14
    Asselah T, Marcellin P. BILN 2061: a major step toward new therapeutic strategies in hepatitis C. J Hepatol 2004; 41: 17881.
  • 15
    McCown MF, Rajyaguru S, Kular S, et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53: 212932.
  • 16
    Zhou Y, Muh U, Hanzelka BL, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007; 282: 2261928.
  • 17
    Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem 2007; 7: 130229.
  • 18
    Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers ? Clin Liver Dis 2011; 15: 62739.
  • 19
    Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96100.
  • 20
    Asselah T. NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C. J Hepatol 2011; 54: 106972.
  • 21
    Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2011; 3: 52732.
  • 22
    Zeuzem S, Soriano V, Asselah T, et al. Interferon (IFN)-free combinationtreatment with HCV NS3/4A protease inhibitor BI 201335 and the non-nucleoside NS 5B inhibitor BI 207127 + /- ribavirin (R): final results of SOUND-C2 and predictors of response. Hepatology 2012; 56(Suppl): 3089A.
  • 23
    Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141: 204755.
  • 24
    Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection. Hepatology 2012; 56(Suppl): LB1.
  • 25
    Gane EJ, Stedman CA, Hyland RH, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON trial. Hepatology 2012; 56(Suppl): 306A.
  • 26
    Osinusi A, et al. High efficacy of GS-7977 in combination with low or full dose Ribavirin for 24 weeks in difficult to treat HCV infected genotype 1 patients. Hepatology 2012; 56(Suppl): LB4.
  • 27
    Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. Hepatology 2012; 56(Suppl): LB2.
  • 28
    Everson GT, Sims KD, Rodriguez-Torres M, et al. An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment-naive patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection. Hepatology 2012; 56(Suppl): LB3.
  • 29
    Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 21624.
  • 30
    Asselah T. A revolution in HCV treatment with direct-acting antivirals: from non-response to eradication. J Hepatol 2012; 57: 4557.
  • 31
    Lok AS, Gardiner DF, Hezode C, et al. Sustained virologicresponse in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV) Hepatology 2012; 56(Suppl): 230A.
  • 32
    Jacobson IM, Sulkowski MS, Gane EJ, et al. VX-222, telaprevir and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C: results of the ZENITH study interferon-free regimen. Hepatology 2012; 56(Suppl): 308A.
  • 33
    Marcellin P, Popa S, Berliba A, et al. ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naïve genotype 1 (GT1) patients. Hepatology 2012; 56(Suppl): 235A.